Significant Antiproliferative Activity Research Articles

Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents

Receptors are proteinous macromolecules which remain in the apo form under normal/unliganded conditions. As the ligand approaches, there are specific stereo-chemical changes in the apo form of the receptor as per the stereochemistry of a ligand. Accordingly, a series of substituted dimethyl-chroman-based stereochemically flexible and constrained Tamoxifen analogs were synthesized as anti-breast cancer agents. The synthesized compounds 19a-e, 20a-e, 21, and 22a-e, showed significant antiproliferative activity against estrogen receptor-positive (ER+, MCF-7) and negative (ER-, MDA MB-231) cells within IC50 value 8.5–25.0 µM. Amongst all, four potential molecules viz 19b, 19e, 22a, and 22c, were evaluated for their effect on the cell division cycle and apoptosis of ER+ and ER- cancer cells (MCF-7 & MDA MB-231cells), which showed that these compounds possessed antiproliferative activity through triggering apoptosis. In-silico docking experiments elucidated the possible affinity of compounds with estrogen receptors-α and -β.

THE FORMULATION AND EVALUATION OF 6-THIOGUANINE AS A NANOSTRUCTURE LIPID CARRIER FOR THE TARGETED DELIVERY OF BREAST CANCER

Objective: The main goal was to avoid all the problems associated with usual breast cancer treatment by using 6-thioguanine as a nanostructure lipid carrier (TG-NLCS). This was accomplished by administering an effective and targeted dose of 6-thioguanine (TG) to the tumour site using a long-lasting and biodegradable delivery system. Methods: A combination of heat homogenization and ultrasonication was used to implement the emulsification process. To obtain the optimal formulation, the prepared formulations were first assessed for particle size, Polydispersity Index (PDI), zeta potential, entrapment efficiency, and drug loading capacity. Additionally, a range of physicochemical characterization techniques were employed, including dissolution studies, melting point determination, Fourier-Transform Infrared (FTIR) spectroscopy, and Field Emission Scanning Electron Microscopy (FESEM), as well as cytotoxicity assessment of TG-NLCs in MCF-7 breast cancer cells. Results: The selected formula, TG03, showed a zeta potential of-13.5±0.27 mV and a particle size of 149±0.55 nm. This was further examined using a FESEM. In the in vitro drug release study, the formula demonstrated better-controlled drug release for 48 h in comparison to other formulations. In addition, the significant anti-proliferation activity of TG-NLCs against the MCF-7 breast cancer cell line. Conclusion: Nanostructured lipid carriers (NLCs) are one type of multifunctional nanoparticle that includes many combinations of lipids and medicines for various delivery routes.

Synthesis, characterization and anti-ovarian cancer activities of novel biphenyl-NHC-gold(I) complexes

Fifteen novel biphenyl-N-heterocyclic carbene (NHC)-gold(I) complexes were designed and synthesized to treat ovarian cancer (OC). Among these, complex Au-1 showed significant antiproliferative activity against A2780 cells and A2780/CDDP cells. Notably, Au-1 exhibited low toxicity to normal ovarian epithelial IOSE-80 cells. Further studies revealed that Au-1 strongly inhibited thioredoxin reductase (TrxR) activity. Collectively, our results demonstrated that Au-1 could be a promising candidate for the treatment of OC.

Development of Benzimidazole-Substituted Spirocyclopropyl Oxindole Derivatives as Cytotoxic Agents: Tubulin Polymerization Inhibition and Apoptosis Inducing Studies.

A series of spirocyclopropyl oxindoles with benzimidazole substitutions was synthesized and tested for their cytotoxicity against selected human cancer cells. Most of the molecules exhibited significant antiproliferative activity with compound 12 p being the most potent. It exhibited significant cytotoxicity against MCF-7 breast cancer cells (IC50 value 3.14±0.50 μM), evidenced by the decrease in viable cells and increased apoptotic features during phase contrast microscopy, such as AO/EB, DAPI and DCFDA staining studies. Compound 12 p also inhibited cell migration in wound healing assay. Anticancer potential of 12 p was proved by the inhibition of tubulin polymerization with IC50 of 5.64±0.15 μM. These results imply the potential of benzimidazole substituted spirocyclopropyl oxindoles, notably 12 p, as cytotoxic agent for the treatment of breast cancer.

Screening of Antioxidative and Antiproliferative Activities of Crude Polysaccharides Extracted from Six Different Plants

Plant polysaccharides have gained interest in medical research for their ability to suppress various diseases, including cancer. However, information on some plant polysaccharides is yet to be uncovered. In this study, we screened crude polysaccharides extracted from six different plants for their antioxidative and antiproliferative activities. Crude polysaccharides were isolated from different parts of some plants using the established extraction protocol. The crude polysaccharides were evaluated for their chemical composition (protein, total sugar, and phenolics), free radical-scavenging activities, and antiproliferative activities against breast cancer MCF-7 cells as well as non-cancerous cells, i.e., human fibroblast MRC-5 cells and Cercopithecus aethiops kidney Vero cells, via an MTT assay and CM20 Incubation Monitoring System (Olympus) for MCF-7. The investigated crude polysaccharides showed significant variations in their chemical constituents and antioxidative properties. Only Moringa seed crude polysaccharide extracts showed significant antiproliferative activities at various concentrations, with an IC50 value of 0.061 mg/mL, which was about 2.6 folds higher on MRC-5 and Vero cell lines. The antiproliferative activities toward cancer cell lines and lack of significant toxicity in the case of normal cells indicate that this extract may be promising as a valuable source for novel cancer therapy.

A Promising Therapeutic Scaffold Fusing Chalcone/Coumarin Targeting Colorectal Cancer: Design, Synthesis, Biological and ADME‐tox Modelling

AbstractEight novel compounds incorporating chalcone and coumarin features, namely chalcone‐coumarin‐ hybrid molecules, were designed, synthetized, and evaluated for their activity against human colorectal carcinoma SW480 cell line. According to the results observed, the hybrid with a 2,3‐dimetoxysubstitution pattern displayed the highest activity at the conditions evaluated, with an IC50 value of 25.18±1.12 μM, being even more active than the reference drug (5‐fluorouracil) and the parental compound (7‐methylcoumarin). In addition, this hybrid compound exhibited significant antiproliferative activity in a time‐ and concentration dependent way, suggesting rather a cytostatic or cytotoxic effect. Moreover, a theoretical drug‐like/pharmacokinetics/toxicological study suggested that the most promising hybrid would have a great chance to advance to further preclinical studies as anti‐cancer therapeutic candidate for oral oncological management. Our study evidently identified the potency of chalcone‐coumarin conjugates, particularly the 2,3‐dimetoxysubstituited molecule to be a prototype drug for further investigations toward novel therapeutics treatments of colorectal cancer.

Iodinated 4,4'-Bipyridines with Antiproliferative Activity Against Melanoma Cell Lines.

In the last decade, biological processes involving halogen bond (HaB) as a leading interaction attracted great interest. However, although bound iodine atoms are considered powerful HaB donors, few iodinated new drugs were reported so far. Recently, iodinated 4,4'-bipyridines showed interesting properties as HaB donors in solution and in the solid state. In this paper, a study on the inhibition activity of seven halogenated 4,4'-bipyridines against malignant melanoma (MM) cell proliferation is described. Explorative dose/response proliferation assays were first performed with three 4,4'-bipyridines by using four MM cell lines and the normal BJ fibroblast cell line as control. Among them, the A375 MM cell line was the most sensitive, as determined by MTT assays, which was selected to evaluate the antiproliferative activity of all 4,4'-bipyridines. Significantly, the presence of an electrophilic iodine impacted the biological activity of the corresponding compounds. The 3,3',5,5'-tetrachloro-2-iodo-4,4'-bipyridine showed significant antiproliferation activity against the A375 cell line, and lower toxicity on BJ fibroblasts. Through in silico studies, the stereoelectronic features of possible sites determining the bioactivity were explored. These results pave the way for the utilization of iodinated 4,4'-bipyridines as templates to design new promising HaB-enabled inhibitors of MM cell proliferation.

In vitro Anti-Proliferative Evaluation of Tridax procumben Plant on Colon Cancer Cell Lines

Every year it is estimated that 9.6 million deaths occur due to cancer disease according to the current census. Therefore, development for novel, safe and efficacious drug for treating cancer is needed. Medical plants are used for the treatment of various types of cancer since ancient times. In the present study, one attempt has been made to explore the medicinal properties of Tridax procumbens L. To prepare plant extract of Tridax procumbens using maceration method and to evaluate in vitro anti-proliferative activity on colon cancer cell line by MTT assay of the plant extract, the Tridax procumbens plant was used involving anti-proliferative potential as hydroalcoholic extract using ethanol and water (70:30v/v). The preliminary phytochemical analysis resulted in the presence of phyto-constituents in hydroalcoholic plant extract and cytotoxic potential was carried out on colon cancer cells (HT-29) using cell viability by MTT assay and plant extract showed significant anti-proliferative activity on colon cancer cells with IC50 value (74.10 μg/ml) as compared with normal epithelial cells (IEC-6) which showed the non-toxic effects. Hence it can be stated that Tridax p has excellent anti-proliferative activity and plant extract can be used in making of herbal based anticancer drugs which can be less expensive and available to all.

In vitro anti-tumoral and immunomodulatory effects of acidic polysaccharides isolated from the fungus Gloeosoma mirabile

Polysaccharides from wood-rooting fungi have attracted attention due to their broad pharmacological properties. Herein, we report the antitumor and immunomodulatory activities of acid polysaccharides isolated from fungi Gloeosoma mirabile. The polysaccharide extracts displayed significant antiproliferative activity against cancer cell lines (MCF-7, HCT-116, U-937) in a dose-dependent manner and induction of IL-6 in macrophage RAW 264.7. Furthermore, flow cytometry analysis showed that high polysaccharide concentrations induced apoptosis by 83% in HL-60 cells. Based on gas chromatography–mass spectrometry (GC-MS) and Fourier transform infra-red (FT-IR) spectroscopy studies, acidic polysaccharides from G. mirabile were mainly composed of arabinose, α-D-galactopyranose and methyl β-D-galactopyranoside.

Abstract 1833: Antioxidant and antiproliferative activities of Ipomoea cairica extracts on three breast cancer cell lines

Abstract Introduction: Breast cancer was the top cause of cancer deaths in 2020 with a death toll of 685 000 worldwide. Breast cancer treatments are based on drug specificity for unique receptors on the surface of some breast cancer types, there is a search for alternative treatments that are inclusive of different breast cancer types. Evidence suggests that antioxidants offer a protective effect against certain cancers. Studies on Ipomoea cairica have reported potential anticancer activity, hence this study aimed to assess the antioxidant and antiproliferative potentials of the extracts of Ipomoea cairica on three breast cancer cell lines. Materials and Methods: The study protocol was approved by the University of the Free State Health Sciences Research Ethics Committee (HSREC), with approval number: UFS-HSD2022/0353/2607-0001. Ipomoea cairica stem and leaves were harvested and identified by Prof. H. Baijnath, Department of Conservation Science, School of Life Sciences, University of KwaZulu-Natal, Durban, South Africa, with specimen number 29 30 DD housed at the Ward Herbarium. The dried plant was extracted sequentially using organic solvents ranging from non-polar to polar and water. The extracts were filtered and concentrated using a rotary evaporator and then evaporated to dryness/lyophilized. Cells were cultured according to standard established procedure. The extracts were subjected to phytochemical analyses. FRAP, DPPH, and ABTS assays were done to examine antioxidant activity and MTT assays were used to evaluate the antiproliferative/cytotoxicity of the extracts against normal (Vero) and breast cancer cell lines (MCF-7, MDA-MB-231, and 4T1). Results and Discussion: Extracts of Ipomoea cairica possess alkaloids, saponins, phenols, flavonoids, phytosterols, tannins, triterpenoids, and anthraquinones. The results from the DPPH and ABTS assays revealed that the methanol and ethyl acetate fractions had significantly the highest antioxidant potentials while the methanol stem extract exhibited the most significant antioxidant activity in the FRAP assay. The DCM stem extract showed the highest antiproliferative activity against all tested cell lines. Conclusion: Extracts of I. cairica possess significant antioxidant properties and antiproliferative activities against a wide array of breast cancer types including the most challenging triple-negative breast cancer. The plant would make for a strong herbal candidate for adjuvant therapy with breast cancer medication. Citation Format: Ayodeji Mathias Adegoke, Doreen Kulabako Kyagaba, Nomonde Hadebe, Nandi Mabaso, Relebohile Patricia Lefojane, Himansu Baijnath, Oyeronke Adunni Odunola, Mamello Patience Sekhoacha. Antioxidant and antiproliferative activities of Ipomoea cairica extracts on three breast cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1833.

Abstract 598: HSK42360: A potent, brain permeable, BRAF paradox breaker for the treatment of BRAF-driven cancers

Abstract Mutations in the BRAF gene are among the most common identified in human cancers approximately 7% of all cancers evaluated, including 70% of melanomas, 50% of thyroid-like cancers, 10% to 20% of colorectal cancers, 13% of serous ovarian cancers, 3-7% of non-small-cell lung cancers, and most recently, hairy cell leukemia. Approved BRAF inhibitors (or +MEKi) against BRAFV600E/K improved initial clinical efficacy. However intrinsic and acquired resistance often arise through BRAF paradoxical activation, limiting durable responses to current BRAF inhibitors. In addition, Approved BRAFi responds poorly to patients with BRAF mutant gliomas or brain metastases, mainly due to limited brain permeability. More effective therapeutic options are therefore needed. To address this clinical challenge, we developed a potent, brain-penetrating paradox breaker HSK42360, as a promising therapy for patients with BRAFV600E mutation, progression or brain metastases following treatment with approved BRAFi or BRAFi/MEKi therapies. HSK42360 is a potent BRAFV600E inhibitor with IC50 value of 5 nM at enzymatic level. Further characterization showed that HSK42360 did not induce homodimer or heterodimer of CRAF with CRAF or BRAF and thereby blocked reactivation of the MAPK pathway in HCT116 cells, whereas Dabrafenib significantly induced RAF dimerization and MAPK reactivation. HSK42360 exhibited significant anti-proliferation activity against multiple tumor cell lines with BRAFV600E, including A375 (melanoma), DU4475 (breast cancer), and COLO205 (colon cancer), but was highly selective for BRAF wild-type cells. HSK42360 was administered orally once daily and showed broad-spectrum antitumor activity in the COLO205 and A375 CDX models. Immunohistochemistry showed a close correlation between the inhibition of tumor growth and ERK1/2 phosphorylation in A375 CDX tumor tissues. To explored the impact of HSK42360 in a brain micro-metastasis model aimed at mimicking early CNS metastatic spread, tumor progression was monitored through BLI (full name) imaging, which revealed that HSK42360 was highly brain penetrant with Kp,uu greater than 1 and triggered potent antitumor activity and prolonged survival in brain metastatic models of melanoma. We next tested the hypothesis that HSK42360 could retain activity in models presenting RAF dimer-driven resistance. Surprisingly, HSK42360 demonstrated promising antitumor effects in the first gen-resistant NRASmA375(NRASQ61K, BRAFV600E) CDX model, supporting its use as a follow-on therapy for current BRAFi resistance. Collectively, these preclinical studies validated that HSK42360 is a novel brain-permeable BRAF paradox breaker that exhibits outstanding antitumor activity in brain metastasis and RAF dimer-driven resistance. Citation Format: Shidong Gao, Yangguang Li, Ju Wang, Pingming Tang, Zongjun Shi, Yao Li, Pangke Yan. HSK42360: A potent, brain permeable, BRAF paradox breaker for the treatment of BRAF-driven cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 598.

Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor

Abstract Background: SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2) is a target of interest for cancer therapy due to its key role in the regulation of RAS/MAPK signal transduction downstream of Receptor Tyrosine Kinases (RTKs). We report here the identification of I-1000233, a novel, highly potent, orally available and brain permeable SHP2 allosteric inhibitor, with potential for the treatment of tumors with dysregulated RTK/RAS/ERK signaling pathways. Material and Methods: High-throughput biological, biochemical and pharmacodynamic (PD) assays were used to inform Structure Activity Relationship studies which led to the identification of a chemical series of potent SHP2 inhibitors. Iterative optimization of physicochemical and pharmacological properties resulted in the identification of I-1000233, an orally available SHP2 inhibitor that showed excellent drug-like properties in preclinical studies. Results: I-1000233 is a potent inhibitor of the SHP2 enzyme in vitro (IC50 = 2 nM) with an exceptionally long residence time on the target. When tested in cell lines, it exhibits significant anti-proliferation activity against brain tumor cells and multiple RAS or EGFR mutant models. It strongly inhibits pERK, a downstream marker of MAPK pathway activity, in a dose dependent manner. Further, in vivo preclinical data confirmed that I-1000233 penetrates the BBB and shows anti-tumor activity, supporting its potential in the treatment of CNS and brain-metastasized tumors. Conclusions: I-1000233 is a potent, selective and orally available SHP2 inhibitor with potential for once-a-day dosing and its brain permeability in humans makes it a promising therapeutic agent against SHP2i responsive brain tumors and metastases. Citation Format: Francesca Puca, Danilo Fabbrini, Alina Ciammaichella, Antonino Missineo, Monica Bisbocci, Martina Nibbio, Annalise Di Marco, Claudia Apicella, Fabrizio Colaceci, Romina Sasso, Daniela Natale, Francesco Scalabrì, Cristina Alli, Vincenzo Pucci, Christian Montalbetti, Alessia Petrocchi, Alessandro Carugo, Carlo Toniatti. Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1975.

Antiproliferative and Apoptosis-Inducing Effects of Ethanolic Extract of Morus Alba Leaves on Human Chronic Myeloid Leukaemia K-562 Cell Lines

The rate of occurrence and prevalence of chronic myeloid leukaemia (CML) are increasing globally, despite it being a rare type of cancer. Morus alba also known as mulberry, has been used in Chinese traditional medicine for a long time to treat various conditions and diseases like hypertension and arthritis. Modern scientific studies have also recognized its medicinal properties, including antioxidant, antidiuretic, antidiabetic, antimicrobial and anticancer. However, its antiproliferative effects on specifically human CML K-562 cell lines remain poorly elucidated. This study aims to determine the antiproliferative effects of M. alba on K-562 cells. In vitro cytotoxicity was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Acridine orange and propidium iodide (AO/PI) dual staining were then employed to assess the method of cell death. The ethanolic extract of M. alba leaves exhibited significant antiproliferative activity, with the lowest maximal half inhibitory concentration (IC50) value observed at 72 hours being 23 µg/mL. Notably, AO/PI staining revealed significant morphological changes, such as membrane blebbing, nuclear fragmentation, and indicator of early apoptosis, and late apoptosis. These results demonstrated that ethanolic extract of M. alba leaves induces apoptotic cell death in K-562 cells. Overall, these findings suggested that ethanolic extract of M. alba leaves exerts potent antiproliferative effects on human CML K-562 cells a in time- and dose-dependent manner.

Design and Synthesis of Novel Anti-proliferative Formononetin Derivatives

aims: aimed to synthesize and evaluate the potential antineoplastic activity of eight newly synthesized FMN derivatives background: Formononetin (FMN) is an isoflavone component of the natural product Astragalus membranaceus. Its well-documented anticancer activity led to the synthesis of new derivatives. objective: This study aimed to synthesize and evaluate the potential antineoplastic activity of eight newly synthesized FMN derivatives. method: Evaluation of the anti-tumor effects and potential mechanisms of action of derivatives using methods such as tetrazolium bromidesalt (MTT), cell cloning, EdU staining, Tunel staining, Transwell chamber , flow cytometry, and enzyme-linked immunosorbent assay (ELISA). result: As indicated by the results, all compounds exhibited toxicity to all three types of cancer cells. Most derivatives exhibited more significant antiproliferative activity than FMN. In comparison with other derivatives, compound 8 displayed the maximum antiproliferative activity, with IC50 value of 8.973 ± 0.296, 7.240 ± 0.208, and 4.378 ± 0.380 μ mol/L for HeLa, A549, and HepG2 cells, separately. In addition, further experiments demonstrated that compound 8 could suppress in vitro proliferation of HepG2 cells, promote HepG2 cell apoptosis, suppress HepG2 cell migration and invasion, and arrest HepG2 cell growth in S phase. The mechanism may be through the reduction of Bcl-2 and Mcl-1 protein expression, the increase of Bax, P53, Fas, Caspase-3 and Caspase-9 protein expression, the reduction of mitochondrial membrane potential and the reduction of ATP production, thus promoting the apoptosis of HepG2 cells. conclusion: Compound 8 may serve as a lead compound with high potential in discovering novel antitumor drugs. Furthermore, it can be explored in depth as an anticancer drug. other: none

STAT3 phosphorylation inhibitor Bt354 exhibits anti-neoplastic activity in glioblastoma multiforme cells.

The high mortality rate of glioblastoma multiforme (GBM), a lethal primary brain tumor, is attributable to postsurgical recurrence. STAT3, an oncogenic protein, is a signal transducer and transcription activator encourages cancer cell migration and proliferation, which results in resistance to therapy. STAT3 inhibition reduces cancer metastasis and improves patient prognosis. Bt354, a small molecule STAT inhibitor, exhibits significant cytotoxic and anti-proliferative activities against certain cancer types. Here, we demonstrated that exposure of GBM cells (U87 MG) to Bt354 had a significant, concentration-dependent growth suppression. Bt354 also induced apoptosis and downregulated the expression of the epithelial-mesenchymal transition genes. Therefore, this study suggests the potential of Bt354 for treating GBM owing to its ability to induce cytotoxicity.

Synthesis and Biological Evaluation of Novel Amino and Amido Substituted Pentacyclic Benzimidazole Derivatives as Antiproliferative Agents.

Newly designed pentacyclic benzimidazole derivatives featuring amino or amido side chains were synthesized to assess their in vitro antiproliferative activity. Additionally, we investigated their direct interaction with nucleic acids, aiming to uncover potential mechanisms of biological action. These compounds were prepared using conventional organic synthesis methodologies alongside photochemical and microwave-assisted reactions. Upon synthesis, the newly derived compounds underwent in vitro testing for their antiproliferative effects on various human cancer cell lines. Notably, derivatives 6 and 9 exhibited significant antiproliferative activity within the submicromolar concentration range. The biological activity was strongly influenced by the N atom's position on the quinoline moiety and the position and nature of the side chain on the pentacyclic skeleton. Findings from fluorescence, circular dichroism spectroscopy, and thermal melting assays pointed toward a mixed binding mode-comprising intercalation and the binding of aggregated compounds along the polynucleotide backbone-of these pentacyclic benzimidazoles with DNA and RNA.

The Effect of Individual Compounds from <i>Rubus chamaemoruson</i> Hemostasis <i>in vitro</i>

Introduction. One of the key tasks of the pharmaceutical industry is the search for new promising compounds – potential drug candidates. Natural objects, especially plants, have long been rich sources of new molecules and are widely used in the global food and pharmaceutical industries. Cloudberry (Rubus chamaemorus L.) is a perennial herb from the Rosaceae family. The fruits and leaves of R. chamaemorus contain a wide variety of polyphenolic secondary metabolites – hydrolysable/condensed tannins and flavonoids. Extracts enriched by polyphenols showed significant antiproliferative activity and inhibition of cell growth, and also induce cell apoptosis. As a result of our previous phytochemical research of R. chamaemorus leaves, five polyphenolic secondary metabolites belonging to the classes of tannins and flavonoids were isolated and characterized.Aim. Screening of previously isolated from R. chamaemorus individual compounds for the hemostasis system in vitro and identification of the most promising compounds for subsequent pharmaceutical development.Materials and methods. Experiments under in vitro conditions were performed on the blood of healthy male donors. The research of the effect on platelet aggregation was carried out according to the Born method on an AT-02 aggregometer (LLC "SPF "Medtech", Russia). Determination of anticoagulant activity was carried out by conventional clotting tests on a Solar CGL 2110 turbidimetric hemocoagulometer (CJSC "SOLAR", Russia). Cytofluorimetric analysis was performed on a NovoCyte instrument (Agilent Technologies, USA).Result and discussion. The influence of the isolated compounds 1–5 on the parameters of activation, platelet aggregation and the coagulation component of hemostasis was studied. At a concentration of 1.0 mg/ml, compounds 1–5 did not affect the fibrinogen concentration and prothrombin time. Compounds 1, 3 and 5 completely suppressed platelet activation at the studied concentrations. Compounds 1 and 3 showed antiaggregation activity comparible to the values of acetylsalicylic acid and are contained in all aqueous and alcoholic extracts of R. сhamaemorus leaves; their quantitative content varies depending on the extraction conditions.Conclusion. Thus, as a result of the screening of individual compounds 1–5 isolated from the leaves of R. chamaemorus their antiaggregating and anticoagulation properties were established. Compounds 1 (4-O-α-L-arabinofuranosylellagic acid) and 3 (quercetin-3-O-β-D-glucuronide) showed antiaggregation activity comparible to that of acetylsalicylic acid, and are the most promising of the studied series of compounds for the subsequent pharmaceutical development of new antiplatelet agents.

Regiodivergent Synthesis and Biological Activities of Indoloquinoline Based Compounds.

Cryptolepine, neocryptolepine, and isocryptolepine have remained popular synthetic targets ever since their isolation from the aqueous extracts of the West African climbing shrub Cryptolepis sanguinolenta. These natural alkaloids were found to contain significant antimalarial, antiproliferative and antimicrobial activities, making them ideal starting points for the development of novel drug candidates. As natural product synthesis is often plagued with step-heavy procedures and poor atom economy, the discovery of synthetic protocols addressing these concerns are sorely needed. In our laboratories, we have devoted our efforts into the development of regiodivergent synthesis whereby two of the indoloquinoline natural products, namely neocryptolepine and 11H-indolo[3,2-c]quinolines, could be assembled in only a few steps from a common and readily available starting material. Our synthetic endeavors to meet these goals include a cascade palladium-catalyzed Suzuki-Miyuara cross-coupling and intramolecular C-N bond formation and a photochemical nitrene insertion strategy. Furthermore, our methods also allowed for the construction of several diversely functionalized natural product derivatives which were subjected to biological evaluations.

Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation.

Epidermal growth factor receptor (EGFR) inhibitors have been used in clinical for the treatment of non-small-cell lung cancer for years. However, the emergence of drug resistance continues to be a major problem. To identify potential inhibitors, molecular docking-based virtual screening was conducted on ChemDiv and Enamine commercial databases using the Glide program. After multi-step VS and visual inspection, a total of 23 compounds with novel and varied structures were selected, and the predicted ADMET properties were within the satisfactory range. Further molecular dynamics simulations revealed that the reprehensive compound ZINC49691377 formed a stable complex with the allosteric pocket of EGFR and exhibited conserved hydrogen bond interactions with Lys 745 and Asp855 of EGFR over the course of simulation. All compounds were further tested in experiments. Among them, the most promising hit ZINC49691377 demonstrated excellent anti-proliferation activity against H1975 and PC-9 cells, while showing no significant anti-proliferation activity against A549 cells. Meanwhile, apoptosis analysis indicated that the compound ZINC49691377 can effectively induce apoptosis of H1975 and PC-9 cells in a dose-dependent manner, while having no significant effect on the apoptosis of A549 cells. The results indicate that ZINC49691377 exhibits good selectivity. Based on virtual screening and bioassays, ZINC4961377 can be considered as an excellent starting point for the development of new EGFR inhibitors.

Discovery of new triterpenoids from Leptopus clarkei and their antiproliferative activity on cancer cells.

Two new triterpenoids (1-2), along with six known analogues (3-8) were obtained from the dried whole plant of Leptopus clarkei. Compound 1 is a 3,4-seco-lupane-type triterpenoid, and compound 2 is a phenylpropanoid-conjugated pentacyclic triterpenoid possessing trans-p-coumaroyl unit attached to oleanane-type skeleton. This is the first report on chemical investigation of the L. clarkei, and the triterpenoid derivatives were found in this plant for the first time. The structures of the new compounds were unequivocally elucidated by HRESIMS and 1D/2D NMR data. Additionally, the isolated compounds were evaluated for theircytotoxicities against four cancer cell lines including HepG2, MCF-7, A549 and HeLa. Notably, compound 2 exhibited the most significant antiproliferative activity with IC50 less than 20 μM for four cancer lines.